Drugs

Fancy Drops Beauty LLC

FDA issued a warning letter to Fancy Drops Beauty LLC (Boulder, CO, United States) on Oct 24, 2024. Subject: Unapproved New Drugs, Misbranded.

From the letter: “Your Fancy Drops products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a) and…”

Boulder, CO, United StatesIssued Oct 24, 2024Posted Nov 5, 2024No close-out recorded

At a glance

What a reviewer notes before reading: findings, citations, the response deadline and what the letter warns of.

Violations
1 finding · 1 issue type
Cited
No CFR or ISO section
Response due
15 working days after receipt of this letter
FDA asks for
1 actions
Named as possible actions
Seizure, injunction
Issued by
Center for Drug Evaluation and Research
Published status
No close-out recorded

AI assisted findings

Model-assisted reading of each issue. Open one to see the FDA text it comes from, and check it against the full letter.

01OtherThe products are unapproved new drugs because they are intended to change eye color, a drug claim, and no approved application is in effect.
Your Fancy Drops products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a) and 331(d).

What FDA requested

  • Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.

FDA Warning Letter

28 paragraphs · 1 section

Text as published on FDA.gov, retrieved Oct 31, 2026. Layout added for reading; the wording is FDA’s. View on FDA.gov (opens in a new tab)

DatedOctober 24, 2024
Sent toRE: 688469
AddressedDear Fancy Drops Beauty LLC

1Letter text

20 paragraphs

This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address https://fancydropsbeauty.com/ in July 2024 and has observed that your website offers “Fancy Drops Color Changing Solutions Eye Drops” in various colors1 (hereinafter referred to as “Fancy Drops products”) for sale in the United States. As described below, your Fancy Drops products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a) and 331(d).

Your Fancy Drops products are especially concerning from a public health perspective. Ophthalmic drug products, which are intended for administration into the eyes, in general pose a greater risk of harm to users because the route of administration for these products bypasses some of the body’s natural defenses.

Based on a review of your website, your Fancy Drops products are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and/or intended to affect the structure or any function of the body. Examples of claims from your website https://fancydropsbeauty.com/ that establish the intended use of these products as drugs include, but may not be limited to, the following:

On the webpage https://fancydropsbeauty.com/:

“Lighten & Brighten Dark Your Eye Color, Speed Up the Eye Color Changing Process.”

On the webpage https://fancydropsbeauty.com/pages/reviews

An image of a bottle of Fancy Drops with the quote “CAN’T BELIEVE FANCY DROPS CHANGED MY EYE COLOR”

Customer review from 02/20/2024: "No blurry vision or pain. About in 3 months it will be noticeable. It works but slow. I can see the differences, now I have blue eye color, like icy blue. I like the result. Thanks!”

Customer review from 05/17/2024: “I’ve had brown eyes for years, and they were blue when I was born! Now, after 5 months, I bought it hoping for green eyes and it works well. It has changed my eyes, and now having green eyes is what I’m most excited about.”

Customer review from 02/22/2024: “I have been using this product for almost 6 months now and I can confidently say that it works for me. I’ve always wanted blue eyes and this Fancy Drops product really made my eye color fade from the dark brown it was in the beginning, slowly to blue”

On the webpage https://fancydropsbeauty.com/pages/about-us:

“Our Eye Color treatments harness the natural properties of plants that work in tandem with proven science to promote clean and gentle color changing process.”

“We are committed to creating thoughtful, modern Color Changing treatments that serve to empower and embrace natural beauty.”

On the webpage https://fancydropsbeauty.com/pages/icy-grey-creative:

“Our Fancy Drops products work by inhibiting the production of Melanin, other pigmentation, and Tyrosinase. But that's not all, our products go beyond this, working at cellular level to Inhibit the enzymes and underlying mechanisms responsible for producing and stimulating pigment-producing cells, [g]iving you a new eye color based on new lower levels of pigmentation.”

“By inhibiting the expression of Melanin and other pigmentation, you increase the color expression of lighter tones, (such as blues, greens, hazels, and light honey shades) and the overall lightness of your eyes.”

Your Fancy Drops products are not generally recognized as safe and effective (GRASE) for the above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p). Subject to certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a). No FDAapproved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for Fancy Drops products. Accordingly, the introduction or delivery for introduction into interstate commerce of these products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).

The violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.

This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.

Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. Your response should be sent to U.S. Food and Drug Administration, CDER/OC/Office of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov.

Sincerely, /S/

Tina Smith, M.S. Captain, U.S. Public Health Service Director Office of Unapproved Drugs and Labeling Compliance Office of Compliance Center for Drug Evaluation and Research U.S. Food and Drug Administration

______________________

1 Fancy Drops products are offered in the following colors: Light Green, Light Blue, Turquoise, Hazel, Sterling Grey, Honey, Dark Green, Dark Blue, Amber, and Purple.

Citations and trends

Each 21 CFR section, ISO 13485 clause and issue type in this letter, how often it appears across all letters, and its trend by the year FDA issued the letters. 2026 runs to Nov 3, 2026, compared with the same dates last year. Select a row or a bar to see those letters in Letters. As cited in this historical letter, not a statement of current requirements.

This letter cites no 21 CFR section or ISO 13485 clause.

Issue types

OtherAI-assigned issue type140letters1finding here
25 letters issued this year vs 30 by the same date last year · -17%

Record details

Issuing center
Center for Drug Evaluation and Research
Issuing office
Center for Drug Evaluation and Research
Location
Boulder, CO, United States
Letter posted date
Nov 5, 2024
Letter issue date
Oct 24, 2024
Addressed to
Not recorded
Inspection dates
Not recorded
Response window
15 working days after receipt of this letter
Read the source clause
Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations.
Record length
959 words · 0 recorded redactions
Published status
No published close-out
Original letter
View on FDA.gov (opens in a new tab)
Dataset last checked
Nov 11, 2026 · How this is built

A response window is not a calculated due date. Source excerpts are selected passages. Finding interpretations and categories are model-assisted. Verify the original letter before relying on a finding.

See the pattern across 1,707 lettersFind letters like this →
Keep exploring

More drug letters

Recent records for the same product type. Your previous filters remain available when you return.

Keep exploring

Find letters like this →
For regulated teams

Put this kind of reading to
work on your own records.

Botable builds and runs a custom AI layer around the software you already use, so your team can do the job you hired them for.

Every letter by dateHow this database is built

FDA Warning Letter Alerts

Share this view

Send the same filters, search and view to a colleague.

You choose what to post or send. Sharing a link does not change access to this site.